Vitura Health Limited · ASX:VIT
Vitura Health — FY2022 Earnings Presentation
28 slides from Vitura Health's earnings presentation, Aug 29, 2022
Slide 1: FY22 Financial Results Presentation Deck
FY22 FINANCIAL RESULTS PRESENTATION DECK Melbourne, Australia, 29 August 2022 – Following the release earlier today of the Company’s ASX Appendix 4E and 2022 Financial Report, Cronos Australia Limited (ASX:CAU) is pleased to release the attached presentation that will be used at the investor webinar
Slide 2: About Cronos Australia Limited
About Cronos Australia Limited (ASX : CAU) Cronos Australia Limited is listed on the ASX (ASX: CAU). • Cronos Australia’s wholly-owned subsidiary, CDA Health Pty Ltd, operates the following businesses: o CanView - the Group operates a successful pharmacy, doctor and patient online portal, CanView, w
Slide 3: FY22 Results Presentation
FY22 Results Presentation Monday 29 August 2022 • ASX Appendix 4E • Declaration of Fully Franked Dividend
Slide 4: Investment Highlights
Investment Highlights Outstanding growth in FY22, extremely well positioned for FY23 Market leading, profitable, and rapidly growing medicinal cannabis company with a deep moat around the CanView platform Profitable and highly cash generative Fully Franked Dividend Declared o Outstanding growth in F
Slide 5: FY22 Financial Highlights
FY22 Financial Highlights Strong results, 200%+ growth across all financial metrics Cronos Australia has delivered strong financial results in FY22, growing in excess of 200% on all financial metrics and positioning the Company for sustainable, scalable growth into FY23 and beyond FY2022 Movement FY
Slide 6: Declaration of Fully Franked Dividend and DRP
Declaration of Fully Franked Dividend and DRP Another first for Cronos Australia, the only ASX listed medicinal cannabis company to deliver a profit and now, the first ASX listed medicinal cannabis company to declare a dividend 1.0 cent 1.0c dividend for every share held Dividend Reinvestment Plan A
Slide 7: Significant revenue growth has continued since FY19
Significant revenue growth has continued since FY19 Revenue for FY22 is $67.0m achieving a 390% CAGR since FY19, the Financial Year CanView was launched $000’s o Sales continue to grow as more prescribers $80,000 and suppliers are onboarded driving volumes through the CanView platform $67.0m $70,000
Slide 8: Financial Overview FY22 Results
Financial Overview FY22 Results
Slide 9: Income statement - strong growth and profitability
Income statement - strong growth and profitability 30 June 2022 30 June 2021 o Total revenue fior FY22 at $67.0m, representing 208% year-on- $'000s $'000s year growth Continuing operations Revenue 66,992 21,712 Cost of sales (41,565) (15,056) o Based on current sales and growth, revenue for FY23 is
Slide 10: Balance sheet - robust financial position
Balance sheet - robust financial position 30 June 2022 30 June 2021 30 June 2022 30 June 2021 $'000s $'000s $'000s $'000s o In excess of $16m of cash ASSETS LIABILITIES AND EQUITY Current assets Current liabilities Cash and cash equivalents 16,077 2,079 o Apart from standard leases, CAU Trade and ot
Slide 11: Cash flow statement - growing positive cashflows
Cash flow statement - growing positive cashflows 30 June 2022 30 June 2021 $'000s $'000s Cash flows from/(used in) operations Receipts from customers 69,607 20,204 Payments made to suppliers and employees (55,473) (19,217) Interest received 8 - Income tax paid (541) (3) Interest and other finance ch
Slide 12: Strategy and Outlook
> > - Strategy and Outlook
Slide 13: The Team
The Team Strategy and execution focused We have assembled an experienced, commercially-focused team to execute on the strategy and create sustainable shareholder value over the long term. Experienced Board combining deep business development, sales, distribution, branding and regulatory expertise in
Slide 14: Strategic Priorities in FY23 to Deliver Growth
Strategic Priorities in FY23 to Deliver Growth Building on a successful FY22, the team has clear strategic priorities for execution to deliver growth in the scope and scale of the company and drive financial results. Growth Strategy Phase 1 – FY22 Growth Strategy Phase 2 – FY23 o ACHIEVED 2800+ phar
Slide 15: We are an Australian market leader
We are an Australian market leader Backed by a market leading business model, financial strength and a large addressable market, Cronos Australia is well positioned for further growth in FY23. o Cronos Australia has delivered outstanding, profitable growth in FY22 with $67m of revenue that generated
Slide 16: Company Overview
Company Overview CanView - Australia’s largest and most trusted medicinal cannabis marketplace
Slide 17: The market we operate in is large and growing rapidly
The market we operate in is large and growing rapidly The medicinal cannabis market continues to grow rapidly in Australia, as cannabinoid therapies become mainstream for patients, doctors and pharmacists. Number of active medicinal cannabis patients Australian medicinal cannabis revenue Q1 2018 – Q
Slide 18: We operate at the downstream end of the value chain
We operate at the downstream end of the value chain Cronos Australia is focused on the high value, downstream end of the value chain for sustainable long-term growth and profitability Genetics Finished Product Clinics, Doctors, Distribution, Cultivation Extraction Manufacturing Patient & Brands Pres
Slide 19: What we do
What we do Laser focussed on the platform, products and clinics Cronos Australia delivers medicinal cannabis prescription, sales and distribution services for doctors, pharmacies and patients throughout Australia. Platform and Products – CanView Clinics – CDA Clinics and Cannadoc o We operate Austra
Slide 20: The CanView Platform
The CanView Platform The CanView platform facilitates all aspects of the medicinal cannabis ecosystem for patients, prescribers, pharmacists and suppliers. Referred Patient Patient books a Prescriber appointment via CanView in person or via Telehealth Medicinal Cannabis Product CanView Registered Do
Slide 21: CanView for Patients
CanView for Patients CanView solves multiple problems for patients that were previously impossible, or very difficult to achieve, without the platform Cumulative patients registered on CanView Q1 FY2021 – Q4 FY2022 8,000 The number of Patients on CanView has grown significantly with 42% quarterly co
Slide 22: CanView for Prescribers
CanView for Prescribers Based on feedback, CanView makes prescribing for medical practitioners streamlined and underpins their compliance obligations for regulators, including AHPRA and the TGA Cumulative prescriber accounts on CanView Q1 FY2021 – Q4 FY2022 Quarter on quarter the number of Prescribe
Slide 23: CanView for Pharmacies
CanView for Pharmacies CanView has integrated significant feedback from pharmacies, which saves them time, delivers on compliance and makes dispensing extremely efficient Cumulative pharmacy accounts on CanView Q1 FY2021 – Q4 FY2022 CanView has onboarded approximately 2,800 3,000 Pharmacies in Austr
Slide 24: CanView for Suppliers
CanView for Suppliers Rather than waiting for monthly updates, CanView provides suppliers with real time data, transparency and forecasting insight Quarterly unit sales through CanView Q1 FY2021 – Q4 FY2022 More than 25 leading suppliers are onboarded on 180,000 Canview, with unit sales growing at a
Slide 25: Australia's leading suppliers have partnered with CanView
Australia’s leading suppliers have partnered with CanView CanView is trusted by Australia’s leading suppliers to sell and distribute the widest range of medicinal cannabis products available. Highly rigorous process to select and Consistency and Investment in Strict product Dedicated help desk onboa
Slide 26: Disclaimer
Disclaimer The following disclaimer applies to this presentation (Presentation) and you are therefore advised to read this disclaimer carefully before reading or making any other use of this Presentation or any information contained in this Presentation. This Presentation has been prepared by Cronos
Slide 27: CanView Overview and Benefits
APPENDIX 1 CanView Overview and Benefits CanView is leveraged by doctors, pharmacies and patients – underpinning access, the patient experience and compliance. Free to use | The platform is free for all users to register and use Compliance | Built in compliance processes for all users to fulfil thei
Slide 28: cronosaustralia.com | ASX: CAU
cronosaustralia.com | ASX: CAU info@cronosaustralia.com | 1300 799 491